Rx Medicare

Latest surveillance data coming through the European Centre for Disease Prevention and Control (ECDC) from virologists and clinicians indicates that the influenza A(H3N2) virus is the predominant strain in Europe so far this season. Based on the data published by ECDC Roche confirms that the oral antiviral Tamiflu (oseltamivir) is fully active against influenza A(H3N2) and influenza B, which currently comprise 94 percent of circulating viruses in Europe this year.

Read More…

Related Posts

• Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses In Animal Studies
• Inviragen Researching Vaccines To Protect Against Pandemic And Seasonal Influenza Viruses
• As Influenza Cases Rise In Europe, Experts Urge Uptake Of H1N1 Vaccine
• NanoViricides Platform Enables Rapid Development Of Robust Nanomedicines Against Influenza And HIV
• Inovio Biomedical, National Microbiology Laboratory, And University Of Pennsylvania To Evaluate Candidate DNA Vaccines Against “Swine” Influenza A
• The Pathogenicity of Pandemic Influenza Viruses
• Vaccinating Kids Against Flu Protects Whole Community, Canadian Study
• AmpVacs A Broadly Protective Synthetic Influenza A Vaccine
• Pandemic Flu, Like Seasonal H1N1, Shows Signs Of Resisting Tamiflu
• Dog Flu: Canine Influenza (CIV) In Dogs
• Dry Winters Linked To Seasonal Outbreaks Of Influenza
• Diagnostic Hybrids Receives FDA Emergency Use Authorization For D3 Ultra 2009 H1N1 Influenza A Virus ID Kit
• Poor Evidence For Effectiveness Of Influenza Vaccines In Elderly
• Amarillo Biosciences Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit In Preventing Influenza-Like Illness In Seniors
• Mandatory Policy Boosts Influenza Vaccination Rate Among Health Care Workers

Tags: against, circulating, efficacy, europe, fully, influenza, percent, remains, tamiflu, viruses

This entry was posted on Wednesday, January 21st, 2009 at 7:01 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.